Actively Recruiting
Phase 1b2 Randomized Study Evaluating Safety and Effects of HS235 Added to Background Treatment in Adults With Pulmonary Arterial Hypertension
Led by 35Pharma Inc., a GSK company · Updated on 2026-10-30
90
Participants Needed
7
Research Sites
35 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, pharmacokinetics, pharmacodynamics, and effectiveness of HS235, an Activin signaling inhibitor, when added to background treatment in adults with pulmonary arterial hypertension PAH. This Phase 1b2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial focuses on adults diagnosed with WHO Group 1 PAH who are symptomatic and on stable background therapies. Participants will receive either the experimental HS235 or a placebo, both given by subcutaneous injection. The study evaluates different doses of HS235 alongside at least two approved PAH background treatments and diuretics. The trial has a sequential study model with randomized allocation and quadruple masking to ensure unbiased results. During the study, participants will undergo various assessments including safety monitoring for adverse events up to 29 weeks. Measurements will include pulmonary hemodynamics confirmed by right heart catheterization at screening, exercise capacity via the 6-minute walk test, and adherence to study procedures. The total study duration extends from screening through treatment and follow-up, concluding by November 2028.
CONDITIONS
Brief Title
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here